



#17
B0
2-2-03

ACG2AUSA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of) Group Art Unit: 1632
)
Gevas et al.) Examiner: M. Borin
)
Appln. No. 09/700,329)
)
Filed: February 8, 2001)
)
For: PREVENTION AND TREATMENT) February 11, 2003
OF HYPERGASTRINEMIA)
)
)
)

Commissioner for Patents
Washington, DC 20231

FOURTH INFORMATION DISCLOSURE STATEMENT

Sir:

Applicant submits to the Examiner the attached Form PTO/SB/08B document listing and this paper pursuant to 37 CFR §1.56 and § 1.97-1.98. Form PTO/SB/08B is attached and a copy of the reference is enclosed herewith. This Information Disclosure Statement is submitted more than three months from the filing date of this application, but before the receipt of a first Office Action.

Pursuant to 37 CFR § 1.97(e)(1), each item of information contained in this Supplemental Information Disclosure Statement (SIDS) was first cited in communication from a foreign patent office in a related international application not more than three months prior to the filing of this SIDS. Therefore, no fees are believed due.

Express Mail No. EU531796897US



00270

PATENT TRADEMARK OFFICE

REMARKS

Listed below is a document cited in the European Search Report mailed on January 31, 2003 in the related European Patent Application No. 99924252.2. A copy of the Report is enclosed, together with a copy of this document.

(EW) HALTER et al., "Evaluation of a Monoclonal Anti-Gastrin Antibody as a Tool for Immunoneutralization of Gastrin During Omeprazole in Treatment in the Rat", Gastroenterology, 96(5): A194 (1989) (ABSTRACT)

The month of publication for document (EW) could not be determined. The year of publication for this document is sufficiently earlier than the effective US filing date and/or the foreign priority date of the present application so that the particular month of publication of the document is not in issue (MPEP 609).

The Examiner is respectfully requested to consider the enclosed document identified in this paper and in the attached Form PTO/SB/08B during the course of examination of this application.

The Director is hereby authorized to charge any deficiency in any fees due with the filing of this paper or credit any overpayment in any fees to our Deposit Account Number 08-3040.

Respectfully submitted,

HOWSON AND HOWSON
Attorneys for Applicant

By Mary E. Bak
Mary E. Bak
Registration No. 31,215
Spring House Corporate Center
Box 457
Spring House, PA 19477
(215) 540-9200